These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 10803815)

  • 1. Tau protein is a potential biological marker for normal pressure hydrocephalus.
    Kudo T; Mima T; Hashimoto R; Nakao K; Morihara T; Tanimukai H; Tsujio I; Koike Y; Tagami S; Mori H; Nakamura Y; Tanaka T; Mori K; Takeda M
    Psychiatry Clin Neurosci; 2000 Apr; 54(2):199-202. PubMed ID: 10803815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased tau protein level in postmortem cerebrospinal fluid.
    Morihara T; Kudo T; Ikura Y; Kashiwagi Y; Miyamae Y; Nakamura Y; Tanaka T; Shinozaki K; Nishikawa T; Takeda M
    Psychiatry Clin Neurosci; 1998 Feb; 52(1):107-10. PubMed ID: 9682942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus.
    Agren-Wilsson A; Lekman A; Sjöberg W; Rosengren L; Blennow K; Bergenheim AT; Malm J
    Acta Neurol Scand; 2007 Nov; 116(5):333-9. PubMed ID: 17922727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic value of tau in cerebrospinal fluid in alzheimer disease].
    Hu Y; He S; Wang J
    Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1377-9. PubMed ID: 11930632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
    Kanai M; Matsubara E; Isoe K; Urakami K; Nakashima K; Arai H; Sasaki H; Abe K; Iwatsubo T; Kosaka T; Watanabe M; Tomidokoro Y; Shizuka M; Mizushima K; Nakamura T; Igeta Y; Ikeda Y; Amari M; Kawarabayashi T; Ishiguro K; Harigaya Y; Wakabayashi K; Okamoto K; Hirai S; Shoji M
    Ann Neurol; 1998 Jul; 44(1):17-26. PubMed ID: 9667589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease.
    Kapaki EN; Paraskevas GP; Tzerakis NG; Sfagos C; Seretis A; Kararizou E; Vassilopoulos D
    Eur J Neurol; 2007 Feb; 14(2):168-73. PubMed ID: 17250725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls.
    Laske C; Stransky E; Leyhe T; Eschweiler GW; Maetzler W; Wittorf A; Soekadar S; Richartz E; Koehler N; Bartels M; Buchkremer G; Schott K
    J Psychiatr Res; 2007 Aug; 41(5):387-94. PubMed ID: 16554070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.
    Brunnström H; Rawshani N; Zetterberg H; Blennow K; Minthon L; Passant U; Englund E
    Alzheimers Dement; 2010 Mar; 6(2):104-9. PubMed ID: 20298970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormalities of tau-protein and beta-amyloid in brain ventricle cerebrospinal fluid.
    Talab R; Valis M; Rehak S; Krejsek J
    Neuro Endocrinol Lett; 2009; 30(5):647-51. PubMed ID: 20035270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan.
    Nishimura T; Takeda M; Nakamura Y; Yosbida Y; Arai H; Sasaki H; Shouji M; Hirai S; Khise K; Tanaka K; Hamamoto M; Yamamoto H; Matsubayashi T; Urakami K; Adachi Y; Nakashima K; Toji H; Nakamura S; Yoshida H
    Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):227-35. PubMed ID: 9646285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ventricular and lumbar cerebrospinal fluid concentrations of Alzheimer's disease biomarkers in patients with normal pressure hydrocephalus and posttraumatic hydrocephalus.
    Brandner S; Thaler C; Lelental N; Buchfelder M; Kleindienst A; Maler JM; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2014; 41(4):1057-62. PubMed ID: 24748118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
    Clark CM; Xie S; Chittams J; Ewbank D; Peskind E; Galasko D; Morris JC; McKeel DW; Farlow M; Weitlauf SL; Quinn J; Kaye J; Knopman D; Arai H; Doody RS; DeCarli C; Leight S; Lee VM; Trojanowski JQ
    Arch Neurol; 2003 Dec; 60(12):1696-702. PubMed ID: 14676043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.
    Riemenschneider M; Wagenpfeil S; Vanderstichele H; Otto M; Wiltfang J; Kretzschmar H; Vanmechelen E; Förstl H; Kurz A
    Mol Psychiatry; 2003 Mar; 8(3):343-7. PubMed ID: 12660807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease.
    Yaka E; Egrilmez MY; Keskinoglu P; Cavdar Z; Genc S; Genc K; Iyilikci L; Yener GG
    Cell Biochem Funct; 2009 Aug; 27(6):395-401. PubMed ID: 19639578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.
    Arai H; Terajima M; Miura M; Higuchi S; Muramatsu T; Machida N; Seiki H; Takase S; Clark CM; Lee VM
    Ann Neurol; 1995 Oct; 38(4):649-52. PubMed ID: 7574462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia.
    Boban M; Grbić K; Mladinov M; Hof PR; Süssmair C; Ackl N; Stanić G; Bader B; Danek A; Simić G
    Coll Antropol; 2008 Jan; 32 Suppl 1():31-6. PubMed ID: 18405055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.